Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans (Q37867193)

24 August 2017

1 reference

title

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans (English)

1 reference

24 August 2017

1

B Ahrén

1 reference

24 August 2017

A Schweizer

2

1 reference

24 August 2017

S Dejager

3

1 reference

24 August 2017

E B Villhauer

4

1 reference

24 August 2017

B E Dunning

5

1 reference

24 August 2017

J E Foley

6

1 reference

24 August 2017

1 September 2011

1 reference

Diabetes, Obesity and Metabolism

24 August 2017

1 reference

24 August 2017

13

1 reference

24 August 2017

775-783

1 reference

24 August 2017

9

1 reference

Glucagon-like peptide-1 7-36: a physiological incretin in man.

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Covalent modifiers: an orthogonal approach to drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Islet somatostatin--microvascular, paracrine, and pulsatile regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Expression of the GLP-1 receptor in mouse, rat, and human pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01414.X

10.1111/J.1463-1326.2011.01414.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference